Topic: treatment response

Support basic, translational, clinical or population research on monosomy 7 AML and other rare, high-risk cytogenetic AML subtypes. Projects should address mechanisms, therapeutic vulnerabilities, biomarkers, treatment response, relapse or survivorship, producing useful diagnostic, therapeutic or trial-enabling findings. The three-year term begins 1 April 2027. Applications are due 1 December 2026 at 13:00 U.S. Eastern Time.

Talk 1. PET based biomarkers of treatment efficacy in temporal lobe epilepsy A critical aspect of drug development involves identifying robust biomarkers of treatment response for use as surrogate endpoints in clinical trials. However, these biomarkers also have the capacity to inform mechanisms of disease pathogenesis and therapeutic efficacy. In this webinar, Dr Bianca Jupp will report on a series of studies using the GABAA PET ligand, [18F]-Flumazenil, to establish biomarkers of treatment response to a novel therapeutic for temporal lobe epilepsy, identifying affinity at this receptor as a